Semaglutide, both oral and subcutaneous, significantly reduces systolic BP in diabetes patients Medha Baranwal3 Jan 2024 10:00 PM ISTChina: A recent systematic review and meta-analysis showed a significant reduction in systolic blood pressure (SBP) with oral or subcutaneous...
Study reveals insights into tacking diabetic kidney disease - with a side order of how anti-obesity drugs work Roshni Dhar13 Dec 2023 9:30 AM ISTData from Australian researchers could partly explain why a trial of a new drug for diabetes, was recently halted because it was found to be so...
Semaglutide treatment benefits patients with heart failure and obesity: STEP-HFpEF trial Dr. Kamal Kant Kohli17 Nov 2023 10:45 AM ISTUSA: Obese patients with heart failure with preserved ejection fraction (HFpEF) treated with 2.4 mg semaglutide showed larger reductions in physical...
Wegovy's heart benefits due to more than weight loss: Novo Nordisk Roshni Dhar16 Nov 2023 5:17 PM ISTNovo Nordisk presented groundbreaking data at the American Heart Association meeting, shedding light on the multifaceted cardiovascular benefits of...
Semaglutide Does Not Appear to Worsen Diabetic Eye Disease in Most Patients, New Study Suggests Dr. Kamal Kant Kohli11 Nov 2023 10:15 AM ISTEven as use of the diabetes drug semaglutide surged in popularity for its ability to help people lower their glucose levels and better manage their...
Dr. Reddy's gets CDSCO Panel Nod To Study weight loss drug Semaglutide injection Dr. Divya Colin18 Oct 2023 6:15 PM ISTNew Delhi: The drug major Dr. Reddy's Laboratories has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug...
Semaglutide improves physical limitations and exercise function in patients of HFpEF with Obesity phenotype regardless of LVEF Dr Riya Dave17 Oct 2023 10:15 AM ISTSemaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, shows promise in the treatment of heart failure patients with the obesity phenotype...
Novo Nordisk to stop once-weekly injectable semaglutide kidney outcomes trial Ruchika Sharma10 Oct 2023 11:00 AM IST"Based on the decision to stop the trial at interim, the process of closing the trial will be initiated. To protect the integrity of the trial, Novo...
Semaglutide significantly controls blood sugar and weight in diabetes patients for up to 3 years Dr. Kamal Kant Kohli9 Oct 2023 10:45 AM ISTNew research presented at this year's Annual Meeting of The European Association for the Study of Diabetes (EASD), Hamburg (2-6 Oct), shows that...
Issues with Weight loss? GLP1 agonists like Semaglutide, Liraglutide may increase risk of pancreatitis, gastroparesis and bowel obstruction Dr. Kamal Kant Kohli6 Oct 2023 10:30 AM ISTUS: Researchers at University of British Columbia have found in a new study that that use of glucagon-like peptide-1 agonists for weight loss compared...
Novo Nordisk eyes to bring blockbuster weight-loss drug Wegovy to India in 2026 Ruchika Sharma1 Oct 2023 1:00 PM ISTNovo charges more than $1300 in the U.S. for a monthly supply and about 300 euros ($317) a month in Germany.
Can semaglutide and empagliflozin combo lower albuminuria in patients with type 2 diabetes? Medha Baranwal30 Sept 2023 11:45 AM ISTDenmark: A randomized and placebo-controlled study investigated the albuminuria-lowering effect of semaglutide addition on top of empagliflozin in...
